JP2014523897A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523897A5 JP2014523897A5 JP2014517952A JP2014517952A JP2014523897A5 JP 2014523897 A5 JP2014523897 A5 JP 2014523897A5 JP 2014517952 A JP2014517952 A JP 2014517952A JP 2014517952 A JP2014517952 A JP 2014517952A JP 2014523897 A5 JP2014523897 A5 JP 2014523897A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- aminomethyl
- ethoxy
- ethyl
- benzylcarbamoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 3,4-difluorophenyl Chemical group 0.000 claims 111
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 125000003118 aryl group Chemical group 0.000 claims 14
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000001408 amides Chemical class 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 7
- IFLKEBSJTZGCJG-UHFFFAOYSA-N 3-methylthiophene-2-carboxylic acid Chemical compound CC=1C=CSC=1C(O)=O IFLKEBSJTZGCJG-UHFFFAOYSA-N 0.000 claims 6
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 claims 4
- 102000003827 Plasma Kallikrein Human genes 0.000 claims 3
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 229940080818 propionamide Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229930195734 saturated hydrocarbon Natural products 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 2
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 claims 2
- KDRURSLBLPTKEJ-IOWSJCHKSA-N 3-acetamido-n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]thiophene-2-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=C(NC(C)=O)C=CS1 KDRURSLBLPTKEJ-IOWSJCHKSA-N 0.000 claims 2
- GKOAHNGAVMWGNA-ZWXJPIIXSA-N 3-acetamido-n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-3-(1-benzothiophen-3-yl)-1-oxopropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]thiophene-2-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2SC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=C(NC(C)=O)C=CS1 GKOAHNGAVMWGNA-ZWXJPIIXSA-N 0.000 claims 2
- HDDOGAGGUYGJLQ-FTJBHMTQSA-N 3-amino-n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-(1,3-thiazol-4-yl)propan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]thiophene-2-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1N=CSC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=C(N)C=CS1 HDDOGAGGUYGJLQ-FTJBHMTQSA-N 0.000 claims 2
- CQSJDKGNONPQOQ-UHFFFAOYSA-N 3-aminothiophene-2-carboxylic acid Chemical compound NC=1C=CSC=1C(O)=O CQSJDKGNONPQOQ-UHFFFAOYSA-N 0.000 claims 2
- BXEAAHIHFFIMIE-UHFFFAOYSA-N 3-chlorothiophene-2-carboxylic acid Chemical compound OC(=O)C=1SC=CC=1Cl BXEAAHIHFFIMIE-UHFFFAOYSA-N 0.000 claims 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 201000011190 diabetic macular edema Diseases 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims 2
- NOORMTUTGSQYIZ-AJQTZOPKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)-3-chlorophenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]benzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=C(Cl)C(CN)=CC=1)NC(=O)C1=CC=CC=C1 NOORMTUTGSQYIZ-AJQTZOPKSA-N 0.000 claims 2
- UXHKCWBMPOSFQY-AJQTZOPKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)-3-fluorophenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]benzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=C(F)C(CN)=CC=1)NC(=O)C1=CC=CC=C1 UXHKCWBMPOSFQY-AJQTZOPKSA-N 0.000 claims 2
- FLWSQHNEOSDTLW-WUFINQPMSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-1,2-oxazole-5-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=NO1 FLWSQHNEOSDTLW-WUFINQPMSA-N 0.000 claims 2
- NXZSBRDPYXWYMY-AJQTZOPKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-2,4-dichlorobenzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=C(Cl)C=C1Cl NXZSBRDPYXWYMY-AJQTZOPKSA-N 0.000 claims 2
- MOIZOCHEDGLANE-AJQTZOPKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-3,4-dichlorobenzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=C(Cl)C(Cl)=C1 MOIZOCHEDGLANE-AJQTZOPKSA-N 0.000 claims 2
- QWEGEWLFUNVAFH-AJQTZOPKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-3,4-difluorobenzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=C(F)C(F)=C1 QWEGEWLFUNVAFH-AJQTZOPKSA-N 0.000 claims 2
- SGUFCVJNEPZKMW-AJQTZOPKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-3-chlorobenzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=CC(Cl)=C1 SGUFCVJNEPZKMW-AJQTZOPKSA-N 0.000 claims 2
- CIHUARIXQZFRDX-XZWHSSHBSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-3-methyl-1h-pyrrole-2-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=C(C)C=CN1 CIHUARIXQZFRDX-XZWHSSHBSA-N 0.000 claims 2
- WQZFDLDYUJSANS-AJQTZOPKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-4-chlorobenzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=C(Cl)C=C1 WQZFDLDYUJSANS-AJQTZOPKSA-N 0.000 claims 2
- HAVAYEXOBKJLDE-AJQTZOPKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-4-fluorobenzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=C(F)C=C1 HAVAYEXOBKJLDE-AJQTZOPKSA-N 0.000 claims 2
- HODNEEJOSRVWQT-JHOUSYSJSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-4-methoxybenzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=C(OC)C=C1 HODNEEJOSRVWQT-JHOUSYSJSA-N 0.000 claims 2
- PQYXYUJVSKCKFL-JHOUSYSJSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-4-methylbenzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=C(C)C=C1 PQYXYUJVSKCKFL-JHOUSYSJSA-N 0.000 claims 2
- UCIXIQRCAGGOJY-AJQTZOPKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]benzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=CC=C1 UCIXIQRCAGGOJY-AJQTZOPKSA-N 0.000 claims 2
- ZBMHBTNVTBWRGV-AJQTZOPKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]cyclohexanecarboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1CCCCC1 ZBMHBTNVTBWRGV-AJQTZOPKSA-N 0.000 claims 2
- NBUOOLFOHRYQNL-IOWSJCHKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]pyridine-3-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=CN=C1 NBUOOLFOHRYQNL-IOWSJCHKSA-N 0.000 claims 2
- KUPKLNUHJXRSMI-IOWSJCHKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]pyridine-4-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=NC=C1 KUPKLNUHJXRSMI-IOWSJCHKSA-N 0.000 claims 2
- GCFLQXXLUPHFNT-XZWHSSHBSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]thiophene-3-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CSC=C1 GCFLQXXLUPHFNT-XZWHSSHBSA-N 0.000 claims 2
- KGASRYBCGZUNAS-ZWXJPIIXSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-pyridin-2-ylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-4-methoxybenzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1N=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=C(OC)C=C1 KGASRYBCGZUNAS-ZWXJPIIXSA-N 0.000 claims 2
- BHVUGAWTPFXTSW-JSOSNVBQSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-pyridin-2-ylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]benzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1N=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=CC=C1 BHVUGAWTPFXTSW-JSOSNVBQSA-N 0.000 claims 2
- YYYMEQVUGUUKPY-WUFINQPMSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-pyridin-3-ylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-3-chlorothiophene-2-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=NC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=C(Cl)C=CS1 YYYMEQVUGUUKPY-WUFINQPMSA-N 0.000 claims 2
- AJYZUIMBRBUFPQ-AJQTZOPKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-pyridin-3-ylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-4-methoxybenzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=NC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=C(OC)C=C1 AJYZUIMBRBUFPQ-AJQTZOPKSA-N 0.000 claims 2
- QLQUHMZRFARDGM-AJQTZOPKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-pyridin-3-ylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-4-methylbenzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=NC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=C(C)C=C1 QLQUHMZRFARDGM-AJQTZOPKSA-N 0.000 claims 2
- IBCRPNPROJRPGD-IHLOFXLRSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-thiophen-2-ylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]benzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1SC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=CC=C1 IBCRPNPROJRPGD-IHLOFXLRSA-N 0.000 claims 2
- OVUYMWPCQQBURI-AJQTZOPKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-3-(4-fluorophenyl)-1-oxopropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]benzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC(F)=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=CC=C1 OVUYMWPCQQBURI-AJQTZOPKSA-N 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- QGLIUKRHFCPRGS-WDYNHAJCSA-N (2r)-n-[(2s)-1-[[4-(aminomethyl)-3-fluorophenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]-3-(4-ethoxyphenyl)-n-methyl-2-(propanoylamino)propanamide Chemical compound C1=CC(OCC)=CC=C1C[C@@H](NC(=O)CC)C(=O)N(C)[C@H](C(=O)NCC=1C=C(F)C(CN)=CC=1)CC1=CC=CC=C1 QGLIUKRHFCPRGS-WDYNHAJCSA-N 0.000 claims 1
- YPOGXTFVOIPEHL-WDYNHAJCSA-N (2r)-n-[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]-3-(4-ethoxyphenyl)-n-methyl-2-(propanoylamino)propanamide Chemical compound C1=CC(OCC)=CC=C1C[C@@H](NC(=O)CC)C(=O)N(C)[C@H](C(=O)NCC=1C=CC(CN)=CC=1)CC1=CC=CC=C1 YPOGXTFVOIPEHL-WDYNHAJCSA-N 0.000 claims 1
- CNHNTLTXVFZCRI-WUFINQPMSA-N (2r)-n-[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-3-(3,4-dichlorophenyl)-1-oxopropan-2-yl]-3-(4-ethoxyphenyl)-2-(propanoylamino)propanamide Chemical compound C1=CC(OCC)=CC=C1C[C@@H](NC(=O)CC)C(=O)N[C@H](C(=O)NCC=1C=CC(CN)=CC=1)CC1=CC=C(Cl)C(Cl)=C1 CNHNTLTXVFZCRI-WUFINQPMSA-N 0.000 claims 1
- KNHURXIHYWTCFE-OIDHKYIRSA-N (2s)-2-[[(2r)-2-[acetyl-[(2-phenylacetyl)amino]amino]-3-(4-ethoxyphenyl)propanoyl]amino]-n-[[4-(aminomethyl)phenyl]methyl]-3-phenylpropanamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)N(C(C)=O)NC(=O)CC1=CC=CC=C1 KNHURXIHYWTCFE-OIDHKYIRSA-N 0.000 claims 1
- BCVMEJPYJNFSMU-WUFINQPMSA-N (2s)-n-[[4-(aminomethyl)phenyl]methyl]-2-[[(2r)-3-(4-ethoxyphenyl)-2-(propanoylamino)propanoyl]amino]-3-phenylpropanamide Chemical compound C1=CC(OCC)=CC=C1C[C@@H](NC(=O)CC)C(=O)N[C@H](C(=O)NCC=1C=CC(CN)=CC=1)CC1=CC=CC=C1 BCVMEJPYJNFSMU-WUFINQPMSA-N 0.000 claims 1
- PHBWBJVPZUGFDM-ZNZIZOMTSA-N (2s,3s)-2-[[(2r)-2-amino-3-(4-ethoxyphenyl)propanoyl]amino]-n-[[4-(aminomethyl)phenyl]methyl]-3-hydroxy-3-phenylpropanamide Chemical compound C1=CC(OCC)=CC=C1C[C@@H](N)C(=O)N[C@H](C(=O)NCC=1C=CC(CN)=CC=1)[C@@H](O)C1=CC=CC=C1 PHBWBJVPZUGFDM-ZNZIZOMTSA-N 0.000 claims 1
- YXLKCGPSLDBIQH-FGUUHEIUSA-N (2s,3s)-n-[[4-(aminomethyl)phenyl]methyl]-2-[[(2r)-3-(4-ethoxyphenyl)-2-(propanoylamino)propanoyl]amino]-3-hydroxy-3-phenylpropanamide Chemical compound C1=CC(OCC)=CC=C1C[C@@H](NC(=O)CC)C(=O)N[C@H](C(=O)NCC=1C=CC(CN)=CC=1)[C@@H](O)C1=CC=CC=C1 YXLKCGPSLDBIQH-FGUUHEIUSA-N 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- DYSJMQABFPKAQM-UHFFFAOYSA-N 1-benzothiophene-2-carboxylic acid Chemical compound C1=CC=C2SC(C(=O)O)=CC2=C1 DYSJMQABFPKAQM-UHFFFAOYSA-N 0.000 claims 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 1
- CFVWQRMYGPSOPB-RPBOFIJWSA-N 2-[[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]acetic acid Chemical compound C1=CC(CN)=CC=C1CNC(=O)[C@@H](NC(=O)[C@@H](CC1CCCCC1)NCC(O)=O)CC1=CC=CC=C1 CFVWQRMYGPSOPB-RPBOFIJWSA-N 0.000 claims 1
- QCXCIYPOMMIBHO-UHFFFAOYSA-N 2-methyl-1,3-thiazole-5-carboxylic acid Chemical compound CC1=NC=C(C(O)=O)S1 QCXCIYPOMMIBHO-UHFFFAOYSA-N 0.000 claims 1
- FQQAMJLKTANPGO-URLMMPGGSA-N 3-acetamido-n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-thiophen-3-ylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]thiophene-2-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC1=CSC=C1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=C(NC(C)=O)C=CS1 FQQAMJLKTANPGO-URLMMPGGSA-N 0.000 claims 1
- CYVSDXJVCZURLD-IHLOFXLRSA-N 3-amino-n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-3-(1-benzothiophen-3-yl)-1-oxopropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]thiophene-2-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2SC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=C(N)C=CS1 CYVSDXJVCZURLD-IHLOFXLRSA-N 0.000 claims 1
- ZGWGSEUMABQEMD-UHFFFAOYSA-N 4-methyl-1,3-thiazole-5-carboxylic acid Chemical compound CC=1N=CSC=1C(O)=O ZGWGSEUMABQEMD-UHFFFAOYSA-N 0.000 claims 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 206010019860 Hereditary angioedema Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010051077 Post procedural haemorrhage Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- 150000002430 hydrocarbons Chemical class 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- ZSQXKFNZFSFYRJ-JHOUSYSJSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)-3-methylphenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]benzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=C(C)C(CN)=CC=1)NC(=O)C1=CC=CC=C1 ZSQXKFNZFSFYRJ-JHOUSYSJSA-N 0.000 claims 1
- PMTPLZNRQDJDQN-FTJBHMTQSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-(1,3-thiazol-4-yl)propan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-3-chlorothiophene-2-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1N=CSC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=C(Cl)C=CS1 PMTPLZNRQDJDQN-FTJBHMTQSA-N 0.000 claims 1
- XXXMZDCXONCQMR-IHLOFXLRSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-(1,3-thiazol-4-yl)propan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-4-methylbenzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1N=CSC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=C(C)C=C1 XXXMZDCXONCQMR-IHLOFXLRSA-N 0.000 claims 1
- FHHIRUSMTLKWSO-WDYNHAJCSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-(1,3-thiazol-4-yl)propan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]benzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1N=CSC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=CC=C1 FHHIRUSMTLKWSO-WDYNHAJCSA-N 0.000 claims 1
- FHGLIRVEEZTGIK-IHLOFXLRSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]-methylamino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-2-methylpropanamide Chemical compound C1=CC(OCC)=CC=C1C[C@@H](NC(=O)C(C)C)C(=O)N(C)[C@H](C(=O)NCC=1C=CC(CN)=CC=1)CC1=CC=CC=C1 FHGLIRVEEZTGIK-IHLOFXLRSA-N 0.000 claims 1
- OQLWNLNQMCZSSV-IHLOFXLRSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]-methylamino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-3-chlorothiophene-2-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N(C)[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=C(Cl)C=CS1 OQLWNLNQMCZSSV-IHLOFXLRSA-N 0.000 claims 1
- HQJNEZIZFKIRDE-SAIUNTKASA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]-methylamino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]benzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N(C)[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=CC=C1 HQJNEZIZFKIRDE-SAIUNTKASA-N 0.000 claims 1
- OTUOSRRHYVCHTB-JHOUSYSJSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-(4-propoxyphenyl)propan-2-yl]benzamide Chemical compound C1=CC(OCCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=CC=C1 OTUOSRRHYVCHTB-JHOUSYSJSA-N 0.000 claims 1
- DCOSMQNHYNPFQB-WUFINQPMSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-2,3,6-trifluoropyridine-4-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC(F)=NC(F)=C1F DCOSMQNHYNPFQB-WUFINQPMSA-N 0.000 claims 1
- WBCSMOPGOQKPQY-XZWHSSHBSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-2,4-dimethyl-1,3-thiazole-5-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=C(C)N=C(C)S1 WBCSMOPGOQKPQY-XZWHSSHBSA-N 0.000 claims 1
- QQYJHIVCRMOELR-URLMMPGGSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-2,6-dichloropyridine-3-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=C(Cl)N=C1Cl QQYJHIVCRMOELR-URLMMPGGSA-N 0.000 claims 1
- ZJPROBBYIUYLCH-AJQTZOPKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-2-chlorobenzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=CC=C1Cl ZJPROBBYIUYLCH-AJQTZOPKSA-N 0.000 claims 1
- MHNXCQNJTDJPBJ-IOWSJCHKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-2-methoxypyridine-4-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=NC(OC)=C1 MHNXCQNJTDJPBJ-IOWSJCHKSA-N 0.000 claims 1
- ALBLURFVONFERJ-AJQTZOPKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-2-methylpyridine-3-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=CN=C1C ALBLURFVONFERJ-AJQTZOPKSA-N 0.000 claims 1
- DBUIROVIMOGHBT-RRPNLBNLSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-3,3,3-trifluoropropanamide Chemical compound C1=CC(OCC)=CC=C1C[C@@H](NC(=O)CC(F)(F)F)C(=O)N[C@H](C(=O)NCC=1C=CC(CN)=CC=1)CC1=CC=CC=C1 DBUIROVIMOGHBT-RRPNLBNLSA-N 0.000 claims 1
- WJCYGURKBSTJEJ-IOWSJCHKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-3,5-dimethyl-1h-pyrrole-2-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=C(C)C=C(C)N1 WJCYGURKBSTJEJ-IOWSJCHKSA-N 0.000 claims 1
- TYGDGTFXXYUGSN-AJQTZOPKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-3-(trifluoromethyl)benzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=CC(C(F)(F)F)=C1 TYGDGTFXXYUGSN-AJQTZOPKSA-N 0.000 claims 1
- XKUREAYXZXNALY-XZWHSSHBSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-5,6-dichloropyridine-3-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CN=C(Cl)C(Cl)=C1 XKUREAYXZXNALY-XZWHSSHBSA-N 0.000 claims 1
- AWZDEIQJFXSYJV-AJQTZOPKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-6-methylpyridine-3-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=C(C)N=C1 AWZDEIQJFXSYJV-AJQTZOPKSA-N 0.000 claims 1
- SJQWETDPGAMVES-JSOSNVBQSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-pyridin-2-ylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-4-chlorobenzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1N=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=C(Cl)C=C1 SJQWETDPGAMVES-JSOSNVBQSA-N 0.000 claims 1
- XTDUCJDRKRNRPM-ZWXJPIIXSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-pyridin-2-ylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-4-methylbenzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1N=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=C(C)C=C1 XTDUCJDRKRNRPM-ZWXJPIIXSA-N 0.000 claims 1
- GWSFNRAHPBVBJY-RRPNLBNLSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-pyridin-3-ylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-1,2-oxazole-5-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=NC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=NO1 GWSFNRAHPBVBJY-RRPNLBNLSA-N 0.000 claims 1
- SYHVZEPQLZQVQE-AJQTZOPKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-pyridin-3-ylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-3-methylbenzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=NC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=CC(C)=C1 SYHVZEPQLZQVQE-AJQTZOPKSA-N 0.000 claims 1
- VEGWZKIUWVMXBY-URLMMPGGSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-pyridin-3-ylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-3-methylthiophene-2-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=NC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=C(C)C=CS1 VEGWZKIUWVMXBY-URLMMPGGSA-N 0.000 claims 1
- COXMDBLAIZHMPI-IOWSJCHKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-pyridin-3-ylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-4-chlorobenzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=NC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=C(Cl)C=C1 COXMDBLAIZHMPI-IOWSJCHKSA-N 0.000 claims 1
- IOKOMILCLYAEGO-IOWSJCHKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-pyridin-3-ylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]benzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=NC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=CC=C1 IOKOMILCLYAEGO-IOWSJCHKSA-N 0.000 claims 1
- MGPOPQVVNMABOI-IOWSJCHKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-1-oxo-3-pyridin-4-ylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]benzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CN=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=CC=C1 MGPOPQVVNMABOI-IOWSJCHKSA-N 0.000 claims 1
- GCTFSBZKSCJATJ-JSOSNVBQSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-3-(1-benzothiophen-3-yl)-1-oxopropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-3-methyl-1h-pyrrole-2-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2SC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=C(C)C=CN1 GCTFSBZKSCJATJ-JSOSNVBQSA-N 0.000 claims 1
- SYUQOCGTPPIJGB-ZWXJPIIXSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-3-(2-fluorophenyl)-1-oxopropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]benzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C(=CC=CC=1)F)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=CC=C1 SYUQOCGTPPIJGB-ZWXJPIIXSA-N 0.000 claims 1
- ORHWIOJJYJCEEN-IOWSJCHKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-3-(3,4-dichlorophenyl)-1-oxopropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]pyridine-2-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=C(Cl)C(Cl)=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=CC=N1 ORHWIOJJYJCEEN-IOWSJCHKSA-N 0.000 claims 1
- GBOFJZGDOGSEJK-URLMMPGGSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-3-(3,4-dichlorophenyl)-1-oxopropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]thiophene-2-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=C(Cl)C(Cl)=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=CS1 GBOFJZGDOGSEJK-URLMMPGGSA-N 0.000 claims 1
- OYMHEDPIXZJWGT-AJQTZOPKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-3-(3-fluorophenyl)-1-oxopropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]benzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=C(F)C=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=CC=C1 OYMHEDPIXZJWGT-AJQTZOPKSA-N 0.000 claims 1
- XRXPBLITZSRMPK-AJQTZOPKSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-3-(4-chlorophenyl)-1-oxopropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]benzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC(Cl)=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=CC=C1 XRXPBLITZSRMPK-AJQTZOPKSA-N 0.000 claims 1
- MNENVOCWAYYIHM-JHOUSYSJSA-N n-[(2r)-1-[[(2s)-1-[[4-(aminomethyl)phenyl]methylamino]-3-(4-methoxyphenyl)-1-oxopropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]benzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H](CC=1C=CC(OC)=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=CC=C1 MNENVOCWAYYIHM-JHOUSYSJSA-N 0.000 claims 1
- JPIQGCNQXOHJHE-SSBOKUKZSA-N n-[(2r)-1-[[(2s,3r)-1-[[4-(aminomethyl)phenyl]methylamino]-3-hydroxy-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]-3-chlorothiophene-2-carboxamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H]([C@H](O)C=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=C(Cl)C=CS1 JPIQGCNQXOHJHE-SSBOKUKZSA-N 0.000 claims 1
- BCBPQVFOASQXEY-YKILCQELSA-N n-[(2r)-1-[[(2s,3r)-1-[[4-(aminomethyl)phenyl]methylamino]-3-hydroxy-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-ethoxyphenyl)-1-oxopropan-2-yl]benzamide Chemical compound C1=CC(OCC)=CC=C1C[C@H](C(=O)N[C@@H]([C@H](O)C=1C=CC=CC=1)C(=O)NCC=1C=CC(CN)=CC=1)NC(=O)C1=CC=CC=C1 BCBPQVFOASQXEY-YKILCQELSA-N 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000008728 vascular permeability Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161505305P | 2011-07-07 | 2011-07-07 | |
| GB1111682.9A GB2494851A (en) | 2011-07-07 | 2011-07-07 | Plasma kallikrein inhibitors |
| GB1111682.9 | 2011-07-07 | ||
| US61/505,305 | 2011-07-07 | ||
| PCT/GB2012/051588 WO2013005045A1 (en) | 2011-07-07 | 2012-07-06 | Benzylamine derivatives as inhibitors of plasma kallikrein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014523897A JP2014523897A (ja) | 2014-09-18 |
| JP2014523897A5 true JP2014523897A5 (https=) | 2015-08-20 |
| JP5921679B2 JP5921679B2 (ja) | 2016-05-24 |
Family
ID=44544412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517952A Expired - Fee Related JP5921679B2 (ja) | 2011-07-07 | 2012-07-06 | 血漿カリクレインの阻害薬としてのベンジルアミン誘導体 |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US9051249B2 (https=) |
| EP (1) | EP2729443B3 (https=) |
| JP (1) | JP5921679B2 (https=) |
| KR (1) | KR101999195B1 (https=) |
| CN (1) | CN103687846B (https=) |
| AR (1) | AR087102A1 (https=) |
| AU (1) | AU2012280064B2 (https=) |
| BR (1) | BR112014000240B1 (https=) |
| CA (1) | CA2841042C (https=) |
| CL (1) | CL2014000032A1 (https=) |
| CO (1) | CO6940413A2 (https=) |
| CY (1) | CY1117200T1 (https=) |
| DK (1) | DK2729443T6 (https=) |
| ES (1) | ES2560612T7 (https=) |
| GB (1) | GB2494851A (https=) |
| HR (1) | HRP20160101T4 (https=) |
| HU (1) | HUE027482T2 (https=) |
| IL (1) | IL230332A (https=) |
| ME (1) | ME02308B (https=) |
| MX (1) | MX343740B (https=) |
| MY (1) | MY185103A (https=) |
| PH (1) | PH12013502677A1 (https=) |
| PL (1) | PL2729443T6 (https=) |
| PT (1) | PT2729443E (https=) |
| RS (1) | RS54509B2 (https=) |
| RU (1) | RU2607045C2 (https=) |
| SI (1) | SI2729443T1 (https=) |
| SM (1) | SMT201600020B (https=) |
| TW (1) | TWI537238B (https=) |
| UA (1) | UA115427C2 (https=) |
| WO (1) | WO2013005045A1 (https=) |
| ZA (1) | ZA201400682B (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012329098B2 (en) | 2011-10-26 | 2017-08-03 | Allergan, Inc. | Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| GB201212081D0 (en) | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
| GB2510407A (en) * | 2013-02-04 | 2014-08-06 | Kalvista Pharmaceuticals Ltd | Aqueous suspensions of kallikrein inhibitors for parenteral administration |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| ES2748434T3 (es) | 2014-01-10 | 2020-03-16 | Univ Cornell | Dipéptidos como inhibidores de inmunoproteasomas humanos |
| EP3193904B1 (en) | 2014-08-18 | 2025-10-01 | Cornell University | Dipeptidomimetics as inhibitors of human immunoproteasomes |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| KR102764027B1 (ko) | 2015-10-15 | 2025-02-07 | 코넬 유니버시티 | 프로테아좀 억제제 및 이의 용도 |
| IL263235B (en) | 2016-05-31 | 2022-07-01 | Kalvista Pharmaceuticals Ltd | History of pyrazoles as plasma kallikrein inhibitors |
| GB201609603D0 (en) * | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201713660D0 (en) * | 2017-08-25 | 2017-10-11 | Kalvista Pharmaceuticals Ltd | Pharmaceutical compositions |
| EP3694605A4 (en) | 2017-10-11 | 2021-10-27 | Cornell University | PEPTIDOMIMETIC PROTEASOME INHIBITORS |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| HUE057912T2 (hu) | 2017-11-29 | 2022-06-28 | Kalvista Pharmaceuticals Ltd | Plazma kallikrein inhibitort tartalmazó dózisformák |
| KR20200143376A (ko) | 2018-03-13 | 2020-12-23 | 샤이어 휴먼 지네틱 테라피즈 인크. | 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도 |
| CN111217670B (zh) * | 2018-11-25 | 2021-04-09 | 中国科学院大连化学物理研究所 | 一种催化还原化合物中羰基为亚甲基的方法 |
| CN113474318A (zh) * | 2019-04-22 | 2021-10-01 | 南京明德新药研发有限公司 | 用作血浆激肽释放酶抑制剂的双环烷类化合物 |
| GB201910125D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of angioedema |
| GB201910116D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of hereditary angioedema |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| WO2021032933A1 (en) * | 2019-08-21 | 2021-02-25 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
| EP4031547B1 (en) | 2019-09-18 | 2024-07-17 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof |
| CN114667289B (zh) | 2019-09-18 | 2025-08-26 | 武田药品工业有限公司 | 杂芳基血浆激肽释放酶抑制剂 |
| GB2591730A (en) | 2019-12-09 | 2021-08-11 | Kalvista Pharmaceuticals Ltd | New polymorphs |
| GB201918994D0 (en) | 2019-12-20 | 2020-02-05 | Kalvista Pharmaceuticals Ltd | Treatments of diabetic macular edema and impaired visual acuity |
| JP7245397B2 (ja) | 2020-03-04 | 2023-03-23 | メッドシャイン ディスカバリー インコーポレイテッド | 複素環化合物 |
| WO2021198534A1 (en) | 2020-04-04 | 2021-10-07 | Oxurion NV | Plasma kallikrein inhibitors for use in the treatment of coronaviral disease |
| TW202228686A (zh) | 2020-10-15 | 2022-08-01 | 英商卡爾維斯塔製藥有限公司 | 血管性水腫之治療 |
| US20230381162A1 (en) | 2020-10-23 | 2023-11-30 | Kalvista Pharmaceuticals Limited | Treatments of angioedema |
| JP2024505596A (ja) | 2021-02-09 | 2024-02-06 | カルビスタ・ファーマシューティカルズ・リミテッド | 遺伝性血管性浮腫の治療 |
| WO2023002219A1 (en) | 2021-07-23 | 2023-01-26 | Kalvista Pharmaceuticals Limited | Treatments of hereditary angioedema |
| WO2023144030A1 (en) | 2022-01-31 | 2023-08-03 | Oxurion NV | Plasma kallikrein inhibitor therapy for anti-vegf sensitization |
| WO2023148016A1 (en) | 2022-02-04 | 2023-08-10 | Oxurion NV | Biomarker for plasma kallikrein inhibitor therapy response |
| US20250281397A1 (en) | 2022-04-27 | 2025-09-11 | Kalvista Pharmaceuticals Limited | Formulations of a plasma kallikrein inhibitor |
| WO2024180100A1 (en) | 2023-02-27 | 2024-09-06 | Kalvista Pharmaceuticals Limited | New solid form of a plasma kallikrein inhibitor |
| WO2025153806A1 (en) | 2024-01-15 | 2025-07-24 | Kalvista Pharmaceuticals Limited | Methods for determining amidolytic activity |
| WO2025172693A1 (en) | 2024-02-13 | 2025-08-21 | Kalvista Pharmaceuticals Limited | Oral sebetralstat for the treatment of an attack of hereditary angioedema |
| WO2025172692A1 (en) | 2024-02-13 | 2025-08-21 | Kalvista Pharmaceuticals Limited | Oral sebetralstat for the treatment of an attack of hereditary angioedema |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
| SE9301911D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptide derivatives |
| US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
| ZA951617B (en) * | 1994-03-04 | 1997-02-27 | Lilly Co Eli | Antithrombotic agents. |
| US5914319A (en) * | 1995-02-27 | 1999-06-22 | Eli Lilly And Company | Antithrombotic agents |
| AU698911B2 (en) * | 1995-04-04 | 1998-11-12 | Merck & Co., Inc. | Thrombin inhibitors |
| JP4179878B2 (ja) * | 2001-02-02 | 2008-11-12 | 中外製薬株式会社 | ペプチド誘導体 |
| GB0205527D0 (en) * | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
| DE10301300B4 (de) * | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein |
| NZ592039A (en) | 2003-08-27 | 2013-03-28 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
| ES2365815T3 (es) * | 2005-12-14 | 2011-10-11 | Bristol-Myers Squibb Company | Análogos de arilpropionamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor xia. |
| JP5322935B2 (ja) | 2006-07-31 | 2013-10-23 | アクティベサイト ファーマシューティカルズ インコーポレイティッド | 血漿カリクレインの阻害薬 |
| DE102006050672A1 (de) * | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
| AR067329A1 (es) * | 2007-06-13 | 2009-10-07 | Bristol Myers Squibb Co | Analogos dipeptidos como inhibidores del factor de coagulacion |
| US8324199B2 (en) | 2008-03-13 | 2012-12-04 | Bristol-Myers Squibb Company | Pyridazine derivatives as factor xia inhibitors |
| EP2512466A4 (en) | 2009-12-18 | 2013-07-03 | Activesite Pharmaceuticals Inc | PRODRUGS OF INHIBITORS OF PLASMATIC KALLICREIN |
| ES2569983T3 (es) | 2010-01-28 | 2016-05-13 | The Medicines Company (Leipzig) Gmbh | Inhibidores de serinproteasa de tipo tripsina y su preparación y uso |
| JP2013121919A (ja) | 2010-03-25 | 2013-06-20 | Astellas Pharma Inc | 血漿カリクレイン阻害剤 |
| EP2590945B1 (en) | 2010-07-07 | 2014-04-30 | The Medicines Company (Leipzig) GmbH | Serine protease inhibitors |
| US9290485B2 (en) | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| WO2012142308A1 (en) | 2011-04-13 | 2012-10-18 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
-
2011
- 2011-07-07 GB GB1111682.9A patent/GB2494851A/en not_active Withdrawn
-
2012
- 2012-07-06 JP JP2014517952A patent/JP5921679B2/ja not_active Expired - Fee Related
- 2012-07-06 RS RS20160011A patent/RS54509B2/sr unknown
- 2012-07-06 ME MEP-2016-6A patent/ME02308B/me unknown
- 2012-07-06 WO PCT/GB2012/051588 patent/WO2013005045A1/en not_active Ceased
- 2012-07-06 AR ARP120102479A patent/AR087102A1/es active IP Right Grant
- 2012-07-06 PT PT127356103T patent/PT2729443E/pt unknown
- 2012-07-06 ES ES12735610T patent/ES2560612T7/es active Active
- 2012-07-06 CN CN201280033711.8A patent/CN103687846B/zh not_active Expired - Fee Related
- 2012-07-06 PH PH1/2013/502677A patent/PH12013502677A1/en unknown
- 2012-07-06 TW TW101124538A patent/TWI537238B/zh not_active IP Right Cessation
- 2012-07-06 UA UAA201401160A patent/UA115427C2/uk unknown
- 2012-07-06 EP EP12735610.3A patent/EP2729443B3/en active Active
- 2012-07-06 SI SI201230437T patent/SI2729443T1/sl unknown
- 2012-07-06 MY MYPI2013702586A patent/MY185103A/en unknown
- 2012-07-06 HR HRP20160101TT patent/HRP20160101T4/hr unknown
- 2012-07-06 BR BR112014000240-1A patent/BR112014000240B1/pt not_active IP Right Cessation
- 2012-07-06 PL PL12735610T patent/PL2729443T6/pl unknown
- 2012-07-06 KR KR1020147003202A patent/KR101999195B1/ko not_active Expired - Fee Related
- 2012-07-06 HU HUE12735610A patent/HUE027482T2/en unknown
- 2012-07-06 AU AU2012280064A patent/AU2012280064B2/en not_active Ceased
- 2012-07-06 CA CA2841042A patent/CA2841042C/en active Active
- 2012-07-06 US US14/131,351 patent/US9051249B2/en active Active
- 2012-07-06 MX MX2014000073A patent/MX343740B/es active IP Right Grant
- 2012-07-06 DK DK12735610.3T patent/DK2729443T6/da active
- 2012-07-06 RU RU2014104226A patent/RU2607045C2/ru active
-
2014
- 2014-01-06 IL IL230332A patent/IL230332A/en active IP Right Grant
- 2014-01-07 CL CL2014000032A patent/CL2014000032A1/es unknown
- 2014-01-28 ZA ZA2014/00682A patent/ZA201400682B/en unknown
- 2014-02-07 CO CO14026538A patent/CO6940413A2/es active IP Right Grant
-
2015
- 2015-04-15 US US14/687,127 patent/US9234000B2/en not_active Expired - Fee Related
-
2016
- 2016-01-20 SM SM201600020T patent/SMT201600020B/it unknown
- 2016-02-17 CY CY20161100135T patent/CY1117200T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014523897A5 (https=) | ||
| RU2014104226A (ru) | Бензиламиновые производные как ингибиторы калликреина плазмы | |
| JP2014502979A5 (https=) | ||
| CN101636154B (zh) | Task-1和task-3离子通道抑制剂 | |
| JP6306609B2 (ja) | 医薬組成物 | |
| RU2486181C2 (ru) | Пиримидилциклопентаны как ингибиторы акт-протеинкиназ | |
| JP4592819B2 (ja) | 抗寄生虫剤 | |
| FI3743406T3 (fi) | Tmem16a-modulaattoreita | |
| HRP20171957T1 (hr) | Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za liječenje raka | |
| JP2007039461A5 (https=) | ||
| JP2011529037A5 (https=) | ||
| JP2016504378A5 (https=) | ||
| JP2020530475A5 (https=) | ||
| JP7159302B2 (ja) | 線維性疾患の治療のための方法 | |
| RU2015142383A (ru) | Новейшие антагонисты trpa1-рецепторов | |
| RU2007119427A (ru) | Соединения, являющиеся ингибиторами гликогенфосфорилазы, и фармацевтические композиции на их основе | |
| JP2013040215A (ja) | 安定な乳化組成物 | |
| RU2018122224A (ru) | Фармацевтическая композиция для лечения или предупреждения nash | |
| JP6957459B2 (ja) | ニトロキシルドナーとしてのｎ−ヒドロキシルスルホンアミド誘導体 | |
| JP2017509694A5 (https=) | ||
| JP2011519832A5 (https=) | ||
| KR101422299B1 (ko) | (2ｒ)-2-〔(4-설포닐)아미노페닐〕프로판아마이드 및 이들 화합물을 함유하는 약학 조성물 | |
| JP2020530475A (ja) | 医薬組成物 | |
| JP2011524362A5 (https=) | ||
| US20100029719A1 (en) | Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors |